NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Retatrutide

Retatrutide

An investigational single peptide designed as a triple agonist of the GLP-1, GIP, and glucagon receptors for obesity and metabolic disease.

Overview

Retatrutide is an investigational peptide designed as an agonist at all three incretin-related receptors: GLP-1, GIP, and glucagon. It was developed for obesity and related metabolic conditions, and reported phase 2 results showed substantial weight loss in adults with obesity. It is not approved and remains in clinical development.

Mechanism

Activation of the GLP-1 and GIP receptors drives appetite reduction and improves glycemic control, while the glucagon component is proposed to increase energy expenditure. The triple-agonist design aims to combine these actions to produce greater weight loss than dual-agonist comparators, and exploratory data also point to effects on liver fat.

Dosing

Clinical protocols have used once-weekly subcutaneous injection with dose escalation. Exact regimens are defined by trial protocols and are not generalizable to research use outside trials.

  • Weekly subcutaneous dosing in the clinical program
  • Dose titration is used to improve gastrointestinal tolerability
  • Research-context dosing outside trials is not established

Expected Effects

  • Large mean weight loss reported in the phase 2 obesity program
  • Improvements in glycemic measures in participants with type 2 diabetes
  • Reductions in liver fat reported in exploratory analyses

Side Effects & Tolerability

Gastrointestinal events such as nausea, vomiting, diarrhea, and constipation are the most common adverse effects and mirror the incretin class. Increases in heart rate have been observed and are monitored as a potential safety signal. Because the compound is investigational, long-term safety is not yet characterized.

Storage

As an investigational research peptide, store lyophilized material cold and desiccated, protected from light and moisture, and follow the supplier certificate of analysis.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.